Loading...
XNSE
ALPA
Market cap19mUSD
Nov 12, Last price  
85.15INR
Name

Alpa Laboratories Ltd

Chart & Performance

D1W1MN
XNSE:ALPA chart
P/E
9.19
P/S
1.59
EPS
9.27
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
5.79%
Revenues
1.12b
+3.41%
1,216,848,000934,367,000819,542,731551,298,721561,085,000567,083,000573,939,000535,900,000656,812,000613,193,000764,219,000848,704,000964,135,0001,105,133,000924,362,0001,087,390,0001,124,519,000
Net income
195m
+16.25%
3,786,0007,965,0009,039,4105,284,518-43,680,000-51,548,000-13,977,00068,461,0009,308,00027,900,0007,939,00018,534,00072,471,000140,917,000126,324,000167,765,000195,031,000
CFO
92m
+153.17%
20,687,0008,632,00049,001,20241,828,75725,583,00080,644,000-18,353,000-218,532,000143,799,00018,400,000-15,900,000177,820,000-16,925,00021,700,000-48,453,00036,487,00092,373,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. It sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to South and Central America, Africa, and Asia, and CIS countries. Alpa Laboratories Limited was founded in 1967 and is based in Indore, India.
IPO date
Aug 01, 2007
Employees
Domiciled in
IN
Incorporated in
IN

Valuation

Title
INR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT